Drug Shortage Report for POTASSIUM PHOSPHATES
Report ID | 168553 |
Drug Identification Number | 00804789 |
Brand name | POTASSIUM PHOSPHATES |
Common or Proper name | POTASSIUM PO4 |
Company Name | SANDOZ CANADA INCORPORATED |
Market Status | MARKETED |
Active Ingredient(s) | POTASSIUM PHOSPHATE DIBASIC POTASSIUM PHOSPHATE MONOBASIC |
Strength(s) | 236MG 224MG |
Dosage form(s) | LIQUID |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 10ML 10LIVI |
ATC code | B05XA |
ATC description | I.V. SOLUTION ADDITIVES |
Reason for shortage | Requirements related to complying with good manufacturing practices. |
Anticipated start date | |
Actual start date | 2023-01-16 |
Estimated end date | 2023-05-15 |
Actual end date | 2023-05-09 |
Shortage status | Resolved |
Updated date | 2023-05-30 |
Company comments | Baxter item : 6750. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v3 | 2022-09-03 | English | Compare |
v2 | 2022-09-02 | French | Compare |
v1 | 2022-09-02 | English | Compare |